News

BTIG Reaffirms Confidence in INmune Bio with Buy Rating

BTIG Reaffirms Confidence in INmune Bio with Buy Rating

BTIG Reaffirms Buy Rating on INmune Bio Shares

BTIG has once again expressed confidence in its Buy rating for INmune Bio Inc. (NASDAQ: INMB), setting a price target of $21.00. This affirmation is driven by the company's innovative strategies in developing drugs for Alzheimer’s disease (AD).

Innovative Approaches to Alzheimer's Disease Treatment

Currently, INmune Bio is validating its XPro anti-inflammatory treatment for AD through a Phase 2 clinical trial. Notably, this trial is uniquely designed to be shorter and may include fewer participants than typical studies in this area.

Insights from the Phase 2 Trial

The trial's EMACC endpoint is especially noteworthy, as it has shown a significant correlation with the CDR-SB gold standard, even though CDR-SB is sometimes viewed as less sensitive to changes in patient conditions. This correlation could be instrumental in helping the FDA recognize the results of the XPro trials, which are expected soon.

Details Regarding the EMACC Endpoint

Introduced in 2017, the EMACC endpoint aims to assess cognitive changes in early Alzheimer's patients with more accuracy than traditional measures, such as CDR and ADAS-Cog. By incorporating five tests that effectively engage early-stage AD patients, EMACC reduces subjective biases that often affect clinical evaluations.

Recent Developments and Financial Moves

Recent analyses reveal that the ongoing Phase 2 trial’s EMACC readouts maintain a blinded variance that comfortably aligns within expected limits, ensuring that any treatment effects are clear and distinguishable. INmune Bio is dedicated to managing inflammation as part of its strategy for AD treatment, aligning with current scientific views on potential combination therapies.

Positive Data and Financial Progress

In other important updates, INmune Bio announced promising data from its Phase II Alzheimer’s Disease trial, which supports the use of the EMACC measure as a primary endpoint. Additionally, the company successfully secured around $13 million through a registered direct offering, attracting investments from both new and existing institutional investors.

Sector Interest and Future Outlook

Scotiabank has recognized the potential of the XPro drug candidate and has initiated coverage on INmune Bio, assigning an Outperform rating. Furthermore, during the recent second-quarter earnings call, the company highlighted its significant progress in its INKmune memory-like natural killer cell oncology platform, along with advancements in its ongoing AD study.

Financial Overview of INmune Bio

As INmune Bio Inc. (NASDAQ: INMB) continues its research into treatments for Alzheimer’s disease, current market insights provide a clearer picture of the company's financial health. Presently, the market capitalization is approximately $123.06 million, reflecting its position within the biotech industry.

Stock Performance and Revenue Metrics

Despite the encouraging initiatives pointed out by BTIG, the company’s stock has experienced notable fluctuations, with a year-to-date total return of -50.71%. This statistic indicates a challenging sentiment surrounding the stock in the market.

Revenue Trends and Financial Health

As of Q2 2024, INmune Bio reported a Revenue Growth decline of -69.53%, which aligns with analyst forecasts for reduced sales this year. A Price to Book ratio of 3.39 implies that the market may be valuing the company's assets highly, despite the ongoing revenue challenges. Fortunately, INmune Bio’s liquid assets exceed its short-term obligations, which reflects financial stability.

Frequently Asked Questions

What is the current stock rating for INmune Bio?

BTIG has maintained a Buy rating on INmune Bio shares, reaffirming its price target of $21.00.

What is the focus of INmune Bio's current trial?

INmune Bio is validating its XPro anti-inflammatory treatment for Alzheimer's disease in a Phase 2 clinical trial.

How does the EMACC endpoint differ from traditional measures?

The EMACC is designed to measure cognitive changes more accurately than traditional metrics like CDR and ADAS-Cog, allowing for a better assessment in early AD patients.

What recent financial developments has INmune Bio experienced?

INmune Bio raised approximately $13 million from a registered direct offering involving institutional investors, boosting its financial position.

How has INmune Bio’s stock performed recently?

The stock has faced significant volatility, showing a total return of -50.71% year-to-date according to recent reports.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Stowers Brings a Transformation CTO Into Its Lab

Updated Category News Views 125

Data Has Become Lab Infrastructure Microscopes may get the glory, but the plumbing behind modern biology is increasingly digital, sprawling and unforgiving. That is why Stowers Institute for Medical Research appointing Brandon Mayer as vice president and chief technology officer on November 19, 2026, deserves more attention than the usual executive-shuffle treatment. This...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 20

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
PinnacleQM Makes Its Enterprise Case More Visible

Updated Category News Views 118

Six pages were never going to carry the weight of a complicated enterprise pitch. PinnacleQM has rebuilt its public face from a basic brochure into a library of more than 50 pages, putting its quality engineering, testing, automation and AI assurance work in clearer view for Australian technology and business buyers. This is not the sort of announcement that changes a...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 83

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 58

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 135

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 0

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
L’Oréal’s Women of Worth Shows Why Brand Patience Matters

Updated Category News Views 138

Twenty-one years is a long time to keep a corporate promise from turning into wallpaper. L’Oréal Paris gathered its 2026 Women of Worth class at the Ebell in Los Angeles on November 18, recognizing 10 nonprofit leaders working on problems that do not yield to a glitzy evening or a tidy slogan. That distinction matters. Cancer survivorship, trafficking prevention,...

Continue Reading

Top 5 Most Recently Viewed Articles

MAGNA-TILES Unveils Exciting Rail Racers To Transform Play

Updated Category News Views 562

MAGNA-TILES Innovates Play with Rail Racers Launch First Fan-Made Invention Reimagines Ball Runs and Takes Magnetic Building to the Next Level MAGNA-TILES, America’s favorite magnetic building toy brand, has introduced an exciting innovation—the Rail Racers. This remarkable new product debuted at the American International Toy Fair, showcasing the creativity of the...

Continue Reading
Discover DDB Miner’s Innovative Approach to Bitcoin Mining

Updated Category News Views 167

Unlocking the Future of Bitcoin Mining DDB Miner, a forward-thinking Bitcoin mining entity, is making significant strides in the cryptocurrency industry. By emphasizing low-cost and efficient operations, DDB Miner is set on a path to redefine how Bitcoin is mined. Their latest operational update sheds light on impressive developments and ambitious plans that promise to...

Continue Reading
Warren Buffett Plans Charitable Giving with New CEO Transition

Updated Category News Views 217

Warren Buffett Speeds Up Charitable Contributions Warren Buffett recently announced that he will accelerate the distribution of his vast fortune, amounting to $149 billion, to his children's charitable foundations. This strategic decision aligns with the responsibilities he feels as a father, recognizing the increasing ages of his children. The Transition to Greg Abel As...

Continue Reading
Understanding the DeFi Technologies Class Action and Its Impact

Updated Category News Views 238

DeFi Technologies Class Action Explained Robbins LLP recently brought to light a class action lawsuit on behalf of investors who bought or acquired shares of DeFi Technologies Inc. (NASDAQ: DEFT). This action covers a specific timeframe, reflecting concerns over the company’s alleged misrepresentation of its business prospects. Investors seeking clarity on this...

Continue Reading
Alibaba's Robotics Innovation: Shaping the Future of AI Tech

Updated Category News Views 199

Alibaba's Bold Move into Robotics Alibaba Group (NYSE: BABA) has embarked on an exciting new venture by launching its own robotics team to compete in the rapidly advancing field of AI-powered physical products. This initiative reflects Alibaba's commitment to integrating artificial intelligence into everyday applications, transforming how technology interacts with the...

Continue Reading